Related Experiment Video
Updated: Mar 8, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Difluoromethylornithine in cancer: new advances
George A Alexiou1, Georgios D Lianos1, Vassileios Ragos1
1Neurosurgical Institute, Ioannina University School of Medicine, Ioannina, GR 451 10, Greece.
Abstract:
Difluoromethylornithine (DFMO; eflornithine) is an irreversible suicide inhibitor of the enzyme ornithine decarboxylase which is involved in polyamine synthesis. Polyamines are important for cell survival, thus DFMO was studied as an anticancer agent and as a chemoprevention agent. DFMO exhibited mainly cytostatic activity and had single agent efficacy as well as activity in combination with other chemotherapeutic drugs for some cancers and leukemias. Herewith, we summarize the current knowledge of the anticancer and chemopreventive properties of DFMO and assess the status of clinical trials.
Insights
Difluoromethylornithine (DFMO) inhibits polyamine synthesis, showing anticancer and chemoprevention potential. Clinical trials are assessing its efficacy as a single agent and in combination therapies for various cancers.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Difluoromethylornithine (DFMO), also known as eflornithine, is an irreversible inhibitor of ornithine decarboxylase.
- Ornithine decarboxylase is a key enzyme in the polyamine synthesis pathway, essential for cell survival.
- Polyamines play a critical role in cellular proliferation and differentiation.
Purpose of the Study:
- To review the current understanding of DFMO's anticancer properties.
- To evaluate DFMO's potential as a chemoprevention agent.
- To assess the ongoing status of clinical trials involving DFMO.
Main Methods:
- Literature review of existing studies on DFMO's mechanism of action and efficacy.
- Analysis of data from preclinical and clinical investigations.
- Summary of findings regarding DFMO as a single agent and in combination therapy.
Main Results:
- DFMO demonstrates primarily cytostatic activity against cancer cells.
- The drug has shown efficacy as a monotherapy and in combination with other chemotherapeutic agents for certain cancers and leukemias.
- DFMO is being investigated for its chemopreventive capabilities.
Conclusions:
- DFMO exhibits significant potential as an anticancer agent and for cancer chemoprevention.
- Further clinical evaluation is warranted to establish its full therapeutic role.
- The summary provides an overview of DFMO's current standing in clinical development.
